22.8 C
New York
Sunday, May 19, 2024

Johnson & Johnson Completes Divestiture Of Ortho-Clinical Diagnostics To The Carlyle Group For $4B

Courtesy of Benzinga.

Related JNJ
Patent Infringement War Continues Between Covidien and J&J Unit – Analyst Blog
FIFA World Cup: China Scores over Brazil – Analyst Blog
Medtronic to Buy Covidien for $42.0 Billion (Fox Business)

Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments.

Under the terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases. The Ortho-Clinical Diagnostics business generated net sales of approximately $1.9 billion in 2013.

Johnson & Johnson will discuss the financial impact of this divestiture during its scheduled quarterly earnings call on July 15, 2014.

Posted-In: News Legal Press Releases

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,196FansLike
396,312FollowersFollow
2,300SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x